Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2021; 31(02): 270-276
DOI: 10.1055/s-0041-1734367
Original Article

Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience

Yashwant Patidar
1   Department of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India
,
Basavaraj,
Amar Mukund
1   Department of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India
,
Shiv K. Sarin
2   Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Portal vein tumor thrombosis (PVTT) is a common complication of hepatocellular carcinoma (HCC) occurring in 30 to 40% of cases. The presence of PVTT in HCC is regarded as an advanced disease that confers poor prognosis and survival. Transarterial chemoembolization (TACE) has traditionally been considered to be contraindicated in cases of PVTT, due to the risk of hepatic infarction, and further deteriorate liver function. We evaluated safety, technical efficacy, and outcomes of TACE in HCC with PVTT.

Methods From search results of the hospital database, out of 652 patients who underwent TACE for HCC, 73 patients of HCC with PVTT were retrospectively evaluated. Post-TACE tumor response by computed tomography (CT)/magnetic resonance imaging (MRI) imaging as per modified response evaluation criteria in solid tumors (mRECIST) criteria, if any occurrence of acute hepatic failure was assessed. Prognostic factors influencing survival were also determined.

Results In our study population, the mean age of the patients was 58 years. The 12- and 24-month survival rates were 59 and 14%, respectively, with an overall median survival of 12.3 months. A total of 58.9% patients had branch portal vein tumor thrombus and 41.1% had tumor thrombus in the main portal vein. We did not encounter any mortality or acute liver failure following TACE in a 30-day period. Both univariate and multivariate analysis revealed Child–Pugh score (p = 0.01) and the extent of tumoral thrombus (p 0.004) as a significant prognostic factor. Patients with branch PVTT, no ascites, and Child–Pugh A had better survival than those having main portal vein tumor thrombus, ascites, and Child–Pugh B.

Conclusion Our study concluded that TACE can achieve good disease control and improved survival in HCC with portal vein invasion despite being considered as a relative contraindication. Technical expertise, selection of patients, such as superselective catheterization and preserved liver function, are the key factors for a safe therapeutic procedure. Child–Pugh score and extent of portal vein invasion were the significant prognostic factors determining survival.

Keywords

hepatocellular carcinoma - portal vein tumor thrombosis - transarterial chemoembolization


Publication History

Article published online:
04 August 2021

© 2021. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379 (9822) 1245-1255
    CrossrefPubMedGoogle Scholar
  • 2 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (01) 9-29
    CrossrefPubMedGoogle Scholar
  • 3 Global battle against cancer won’t be won with treatment alone–effective prevention measures urgently needed to prevent cancer crisis. Cent Eur J Public Health 2014; 22 (01) 23-28, 28
    PubMedGoogle Scholar
  • 4 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146 (07) 1691-700.e3
    CrossrefPubMedGoogle Scholar
  • 5 Llovet JM, Ricci S, Mazzaferro V. et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
    CrossrefPubMedGoogle Scholar
  • 6 Llovet JM, Bustamante J, Castells A. et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29 (01) 62-67
    CrossrefPubMedGoogle Scholar
  • 7 Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001; 48 (01) 103-109
    CrossrefPubMedGoogle Scholar
  • 8 Kalva SP, Pectasides M, Liu R. et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol 2014; 37 (02) 381-387
    CrossrefPubMedGoogle Scholar
  • 9 Prajapati HJ, Dhanasekaran R, El-Rayes BF. et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013; 24 (03) 307-315
    CrossrefPubMedGoogle Scholar
  • 10 Silva JP, Berger NG, Tsai S. et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford 2017; 19 (08) 659-666
    CrossrefPubMedGoogle Scholar
  • 11 Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 2013; 13: 60
    CrossrefPubMedGoogle Scholar
  • 12 Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 3rd ed. Tokyo, Japan: Kanehara & Co., Ltd 2003
  • 13 Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol 2016; 22 (32) 7289-7300
    CrossrefPubMedGoogle Scholar
  • 14 Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 (01) 61-74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Ye JZ, Zhang YQ, Ye HH. et al. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol 2017; 17: 141-147
    Google Scholar
  • 16 Chung JW, Park JH, Han JK. et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198 (01) 33-40
    CrossrefPubMedGoogle Scholar
  • 17 Luo J, Guo RP, Lai EC. et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18 (02) 413-420
    CrossrefPubMedGoogle Scholar
  • 18 Niu ZJ, Ma YL, Kang P. et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012; 29 (04) 2992-2997
    CrossrefPubMedGoogle Scholar
  • 19 Tawada A, Chiba T, Ooka Y. et al. Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma. Anticancer Res 2014; 34 (08) 4231-4237
    Google Scholar
  • 20 Acharya SK. Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol 2014; 4 (Suppl. 03) S27-S33
    CrossrefPubMedGoogle Scholar
  • 21 Georgiades CS, Hong K, D’Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16 (12) 1653-1659
    CrossrefPubMedGoogle Scholar
  • 22 Chern MC, Chuang VP, Liang CT, Lin ZH, Kuo TM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors. J Vasc Interv Radiol 2014; 25 (01) 32-40
    CrossrefPubMedGoogle Scholar
  • 23 Kim JH, Yoon HK, Kim SY. et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29 (12) 1291-1298
    CrossrefPubMedGoogle Scholar
  • 24 Yoo JJ, Lee JH, Lee SH. et al. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PLoS One 2014; 9 (11) e113926
    CrossrefPubMedGoogle Scholar
  • 25 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258 (02) 627-634
    CrossrefPubMedGoogle Scholar
  • 27 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
    CrossrefPubMedGoogle Scholar
  • 28 Cho YY, Lee M, Kim H-C. et al. Radioembolization Is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: A propensity score analysis. PLoS One 2016; 11 (05) 0154986
    Google Scholar
  • 29 Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995; 165 (02) 315-321
    CrossrefPubMedGoogle Scholar
  • 30 Yadav A, Hariprasad S, Gupta S. et al. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J 2014; 29 (06) 430-436
    CrossrefPubMedGoogle Scholar